RonaldStuartFleischmannMD

Psychiatry • Dallas, TX

Physician

Join to view full profile

Dr. Fleischmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fleischmann's full profile

Already have an account?

Office
8411 Preston Rd
712
Dallas, TX 75225
Phone+1 214-360-0720

Fax+1 214-360-9565
Is this information wrong?

Summary

I am a board certified psychiatrist in Dallas TX, certified in psychoanalysis by the American Psychoanalytic Association. I treat adults, teens and couples with therapy and medication when indicated. The best way to see the suitability of a therapist is to check their on-line reviews (Google and Health Grades).

Fleischmann Ronald MD

Your domain registration is pending. Check back in an hour Psychiatrist in Dallas, TX I was referred to Dr Fleischmann by another professional therapist based o

Education & Training

Rutgers Robert Wood Johnson Medical SchoolResidency, Psychiatry, 1973 - 1975
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 1970 - 1971
Hoboken University Medical CenterInternship, Internal Medicine, 1969 - 1970
New York Medical CollegeClass of 1969

Certifications & Licensure

NJ State Medical License 1974 - Present
NY State Medical License 1970 - Present
TX State Medical License 1985 - 2025
CA State Medical License 2001 - 2024
American Board of Psychiatry and Neurology Psychiatry

Publications & Presentations

PubMed

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R, Mease PJ, Schwartzman S, Hwang L, Soma K, Connell CA, Takiya L, Bananis E> ;Clin. Rheumatol.. 2016-10-12
Early Disease Activity or Clinical Response Predict Long-Term Outcomes with Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
van der Heijde D, Deodhar A, Fleischmann R, Mease PJ, Rudwaleit M, Nurminen T, Davies BPharm O> ;Arthritis Care Res (Hoboken). 2016-10-01
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Pe...> ;RMD Open. 2015-01-01
Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study.
Gladman D, Fleischmann R, Szegvari B, Peterson L, Mease PJ> ;Value Health. 2014-11-01
Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter st...
Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ> ;Arthritis Care Res (Hoboken). 2014-07-01
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase II...
van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, Mease PJ> ;Ann. Rheum. Dis.. 2014-01-01
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study ...
Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D> ;Ann. Rheum. Dis.. 2014-01-01
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, S...> ;Ann. Rheum. Dis.. 2012-04-01
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, S...> ;Ann. Rheum. Dis.. 2011-03-01
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, K...> ;Ann. Rheum. Dis.. 2010-01-01
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the...
Fleischmann, R.,Vencovsky, J.,van Vollenhoven, R. F.,Borenstein, D.,Box, J.,Coteur, G.,Goel, N.,Brezinschek, H. P.,Innes, A.,Strand, V.> ;Ann. Rheum. Dis.. 2008 Nov 19
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De ...> ;Ann. Rheum. Dis.. 2008-12-01
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PLCM, Fleischmann R, Weisman MH, Weinblatt ME> ;Ann. Rheum. Dis.. 2007-11-01
Long term safety of etanercept in elderly subjects with rheumatic diseases.
Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P> ;Ann. Rheum. Dis.. 2006-03-01
The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.
Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, W...> ;Arthritis Rheum.. 1999-10-01
Join now to see all